Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03).
Tomás JF, Montalbán C, De Sevilla AF, Martínez-López J, Díaz N, Canales M, Martínez R, Sánchez-Godoy P, Caballero MD, Peñalver J, Prieto E, Salar A, Burgaleta C, Queizán JA, Bajo R, De Oña R, De La Serna J. Tomás JF, et al. Leuk Lymphoma. 2011 Mar;52(3):409-16. doi: 10.3109/10428194.2010.543717. Epub 2011 Jan 28. Leuk Lymphoma. 2011. PMID: 21275633 Clinical Trial.
Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series.
Guisado-Vasco P, Arranz-Saez R, Canales M, Cánovas A, Garcia-Laraña J, García-Sanz R, Lopez A, López JL, Llanos M, Moraleda JM, Rodriguez J, Rayón C, Sabin P, Salar A, Marín-Niebla A, Morente M, Sánchez-Godoy P, Tomás JF, Muriel A, Abraira V, Piris MA, Garcia JF, Montalban C; Spanish Hodgkin Lymphoma Study Group. Guisado-Vasco P, et al. Among authors: tomas jf. Leuk Lymphoma. 2012 May;53(5):812-9. doi: 10.3109/10428194.2011.635861. Epub 2012 Jan 31. Leuk Lymphoma. 2012. PMID: 22185637
A randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results.
López-Guillermo A, Canales MÁ, Dlouhy I, Mercadal S, Briones J, Martín García-Sancho A, Sancho JM, Moraleda JM, Terol MJ, Salar A, Palomera L, Gardella S, Jarque I, Ferrer S, Bargay J, López A, Panizo C, Muntañola A, Montalbán C, Conde E, Hernández MT, Soler A, García Marco JA, Deben G, Marín J, Tomás JF; PETHEMA/GELTAMO/GELCAB Spanish Intergroup. López-Guillermo A, et al. Among authors: tomas jf. Leuk Lymphoma. 2022 Jan;63(1):93-100. doi: 10.1080/10428194.2021.1971216. Epub 2021 Aug 30. Leuk Lymphoma. 2022. PMID: 34459702 Clinical Trial.
Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide.
Martínez-López J, Rivero A, Rapado I, Montalbán C, Paz-Carreira J, Canales M, Martínez R, Sánchez-Godoy P, Fernández de Sevilla A, Peñalver FJ, Gonzalez M, Prieto E, Salar A, Burgaleta C, Queizán JA, Peñarrubia MJ, Monteagudo MD, Cabrera C, De la Serna J, Tomás JF. Martínez-López J, et al. Among authors: tomas jf. Leuk Lymphoma. 2009 Aug;50(8):1283-9. doi: 10.1080/10428190903040006. Leuk Lymphoma. 2009. PMID: 19557622
First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial.
Salar A, Domingo-Domenech E, Panizo C, Nicolás C, Bargay J, Muntañola A, Canales M, Bello JL, Sancho JM, Tomás JF, Rodríguez MJ, Peñalver FJ, Grande C, Sánchez-Blanco JJ, Palomera L, Arranz R, Conde E, García M, García JF, Caballero D, Montalbán C; Grupo Español de Linfomas/Trasplante de Médula Ósea (GELTAMO). Salar A, et al. Among authors: tomas jf. Lancet Haematol. 2014 Dec;1(3):e104-11. doi: 10.1016/S2352-3026(14)00021-0. Epub 2014 Nov 19. Lancet Haematol. 2014. PMID: 27029228
Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma.
Salar A, Domingo-Domenech E, Panizo C, Nicolás C, Bargay J, Muntañola A, Canales M, Bello JL, Sancho JM, Tomás JF, Rodríguez MJ, Peñalver J, Grande C, Sánchez-Blanco JJ, Palomera L, Arranz R, Conde E, García M, García JF, Caballero D, Montalbán C. Salar A, et al. Among authors: tomas jf. Blood. 2017 Oct 12;130(15):1772-1774. doi: 10.1182/blood-2017-07-795302. Epub 2017 Aug 11. Blood. 2017. PMID: 28801448 Free article. Clinical Trial. No abstract available.
Predictive value of interim ¹⁸F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment.
González-Barca E, Canales M, Cortés M, Vidal MJ, Salar A, Oriol A, Bargay J, Bello JL, Sánchez JJ, Tomás JF, Donato E, Ferrer S, Caballero D; GELTAMO (Grupo Español de Linfoma y Trasplante de Médula Ósea). González-Barca E, et al. Among authors: tomas jf. Nucl Med Commun. 2013 Oct;34(10):946-52. doi: 10.1097/MNM.0b013e328363c695. Nucl Med Commun. 2013. PMID: 23880897 Clinical Trial.
Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention.
Esteve J, Escoda L, Martín G, Rubio V, Díaz-Mediavilla J, González M, Rivas C, Alvarez C, González San Miguel JD, Brunet S, Tomás JF, Tormo M, Sayas MJ, Sánchez Godoy P, Colomer D, Bolufer P, Sanz MA; Spanish Cooperative Group PETHEMA. Esteve J, et al. Among authors: tomas jf. Leukemia. 2007 Mar;21(3):446-52. doi: 10.1038/sj.leu.2404501. Epub 2007 Jan 4. Leukemia. 2007. PMID: 17205057 Clinical Trial.
Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients.
González-Barca E, Canales MA, Salar A, Ferrer S, Domingo-Domenech E, Vidal MJ, Grande C, Bargay J, Gardella S, Oriol A, Briones J, García-Frade J, Bello JL, Sánchez-Blanco JJ, Peñalver FJ, Tomás JF, Asensio A, López A, Caballero D; GELTAMO Group (Grupo Español de Linfoma y Trasplante de Médula Ósea). González-Barca E, et al. Among authors: tomas jf. Acta Haematol. 2016;136(2):76-84. doi: 10.1159/000444625. Epub 2016 May 18. Acta Haematol. 2016. PMID: 27188649 Clinical Trial.
112 results